Markus Zettl, PhD has more than 15 years experience in research and development in the area of Immuno-Oncology bringing multiple drug candidates to the clinic as well as providing preclinical and translational support for Phase 1 to 2 clinical studies. Before joining CureVac as Vice President leading the Oncology Research & Development organisation, he worked at Boehringer Ingelheim and the mid-size Pieris Pharmaceuticals. Furthermore, he held academic positions at the Laboratory of Molecular Biology (LMB) Cambridge and performed his Ph.D at the European Molecular Biology Laboratory (EMBL) Heidelberg and CRUK, London. Throughout his career he published several high impact publications including Cell and Science and is an inventor on multiple patents.